Development of bispecific antibodies in China: overview and prospects

Jing Zhang; Jizu Yi; Pengfei Zhou

doi:10.1093/abt/tbaa011

Properties of the major component of a peptic digest of rabbit antibody

Nisonoff, A; Wissler, FC; Lipman, LN

Hybrid hybridomas and their use in immunohistochemistry

Milstein, C; Cuello, AC

Structural and functional characterization of the trifunctional antibody catumaxomab

Chelius, D; Ruf, P; Gruber, P

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Klinger, M; Brandl, C; Zugmaier, G

"Diabodies": small bivalent and bispecific antibody fragments

Holliger, P; Prospero, T; Winter, G

Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens

Kitazawa, T; Esaki, K; Tachibana, T

Next generation antibody therapeutics using Bispecific antibody technology

Igawa, T

Engineering a bispecific antibody with a common light chain: identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974

Shiraiwa, H; Narita, A; Kamata-Sakurai, M

The making of bispecific antibodies

Brinkmann, U; Kontermann, RE

Bispecific antibodies and antibody–drug conjugates for cancer therapy: technological considerations

Shim, H

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

Suurs, FV; Lub-de Hooge, MN; Vries, EGE

Alternative molecular formats and therapeutic applications for bispecific antibodies

Spiess, C; Zhai, Q; Carter, PJ

Design and production of Bispecific antibodies

Wang, Q; Chen, Y; Park, J

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

Schaefer, W; Regula, JT; Bahner, M

Efficient generation of stable bispecific IgG1 by controlled fab-arm exchange

Labrijn, AF; Meesters, JI; Goeij, BE

Naturally occurring antibodies devoid of light chains

Hamers-Casterman, C; Atarhouch, T; Muyldermans, S

Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules

Wu, C; Ying, H; Bose, S

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

Moore, PA; Zhang, W; Rainey, GJ

Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin fc fragment (Fcab)

Kainer, M; Antes, B; Wiederkum, S

Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design

Von Kreudenstein, TS; Escobar-Carbrera, E; Lario, PI

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells

Reusch, U; Burkhardt, C; Fucek, I

A robust heterodimeric fc platform engineered for efficient development of bispecific antibodies of multiple formats

Moore, GL; Bernett, MJ; Rashid, R

A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1

De Nardis, C; Hendriks, LJA; Poirier, E

APVO210: a Bispecific anti-CD86-IL-10 fusion protein (ADAPTIR) to induce antigen-specific T regulatory type 1 cells

Pellerin, L; Chen, P; Gregori, S

Biology drives the discovery of bispecific antibodies as innovative therapeutics

Nie, S; Wang, Z; Moscoso-Castro, M

Bispecific antibodies: a mechanistic review of the pipeline

Labrijn, AF; Janmaat, ML; Reichert, JM

Bispecific antibody based therapeutics: strengths and challenges

Thakur, A; Huang, M; Lum, LG

Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

Ridgway, JB; Presta, LG; Carter, P

Enhancing antibody fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG

Gunasekaran, K; Pentony, M; Shen, M

Highlights of 2019 protein engineering summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic

Li, H; Li, Y; Wang, C

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

Brischwein, K; Schlereth, B; Guller, B

Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6

Stadler, CR; Bähr-Mahmud, H; Plum, LM

Generation and characterization of a Bispecific antibody targeting both PD-1 and c-MET

Wu, Y; Yu, M; Sun, Z

Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems

Verma, R; Boleti, E; George, AJT

Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties

Vendel, MC; Favis, M; Snyder, WB

The development of a recombinant scFv monoclonal antibody targeting canine CD20 for use in comparative medicine

Jain, S; Aresu, L; Comazzi, S

A novel anti-HIV-1 bispecific bNAb-lectin fusion protein engineered in a plant-based transient expression system

Seber Kasinger, LE; Dent, MW; Mahajan, G

Expression and characterization of bispecific single-chain Fv fragments produced in transgenic plants

Fischer, R; Schumann, D; Zimmermann, S

Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system

Xu, Y; Lee, J; Tran, C

Unexpected instabilities explain batch-to-batch variability in cell-free protein expression systems

Hunter, DJB; Bhumkar, A; Giles, N

High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells

Jäger, V; Büssow, K; Wagner, A

Bioreactor scale up and protein product quality characterization of piggyBac transposon derived CHO pools

Rajendra, Y; Balasubramanian, S; Peery, RB

Generation of high expressing Chinese hamster ovary cell pools using the leap-in transposon system

Balasubramanian, S; Peery, RB; Minshull, J

The accelerated atherogenesis of venous grafts might be attributed to aggravated concentration polarization of low density lipoproteins: a numerical study

Fan, Z; Sun, A; Liu, X

A study of monoclonal antibody-producing CHO cell lines: what makes a stable high producer?

Chusainow, J; Yang, YS; Yeo, JHM

Determination of Chinese hamster ovary cell line stability and recombinant antibody expression during long-term culture

Bailey, LA; Hatton, D; Field, R

Q6B specifications: test procedures and acceptance criteria for biotechnological/biological products

Q5A viral safety evaluation of biotechnology products derived from cell lines of human or animal Origi

Fc engineering for developing therapeutic Bispecific antibodies and novel scaffolds

Liu, H; Saxena, A; Sidhu, SS

Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo

Han, H; Ma, J; Zhang, K

A tetravalent single chain diabody (CD40/HER2) efficiently inhibits tumor proliferation through recruitment of T cells and anti-HER2 functions

Lu, L; Liu, NB; Fan, KH

Structural considerations for functional anti-EGFR x anti-CD3 bispecific diabodies in light of domain order and binding affinity

Asano, R; Nagai, K; Makabe, K

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint

Koopmans, I; Hendriks, D; Samplonius, DF

Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing

Zeidler, R; Reisbach, G; Wollenberg, B

Overexpression, purification, characterization, and pathogenicity of Vibrio harveyi hemolysin VHH

Zhong, YB; Zhang, XH; Chen, JX

Limitation of the MTT and XTT assays for measuring cell viability due to superoxide formation induced by nano-scale TiO2

Wang, SG; Yu, HT; Wickliffe, JK

Effect of 14-3-3 tau protein on differentiation in BeWo choriocarcinoma cells

Cheng, Y; Hu, R; Jin, H

Antitumor activity of a novel Bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits Heregulin-induced activation of ErbB3

McDonagh, CF; Huhalov, A; Harms, BD

Anti-PSMA/CD3 Bispecific antibody delivery and antitumor activity using a polymeric depot formulation

Leconet, W; Liu, H; Guo, M

Targeting bladder cancer using activated T cells armed with bispecific antibodies

Ma, J; Ge, J; Xue, X

A T-cell-engaging B7-H4/CD3-bispecific fab-scFv antibody targets human breast cancer

Iizuka, A; Nonomura, C; Ashizawa, T

A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity

Mack, M; Riethmuller, G; Kufer, P

Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study

Chan, JK; Hamilton, CA; Cheung, MK

Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation

Grabert, RC; Cousens, LP; Smith, JA

Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 x anti-CMV bispecific antibody

Lum, LG; Ramesh, M; Thakur, A

Brucella peptide cross-reactive major histocompatibility complex class I presentation activates SIINFEKL-specific T cell receptor-expressing T cells

Harms, JS; Khan, M; Hall, C

Immunogenicity testing of therapeutic protein products-developing and validating assays for anti-drug antibody detection

The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct

Brandl, C; Haas, C; d'Argouges, S

Bispecific antibody approach for improved melanoma-selective PD-L1 immune checkpoint blockade

Koopmans, I; Hendriks, M; Ginkel, RJ

CA-170 - a potent small-molecule PD-L1 inhibitor or not?

Musielak, B; Kocik, J; Skalniak, L

Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules

Seifert, O; Rau, A; Beha, N

Expanding the boundaries of biotherapeutics with Bispecific antibodies

Husain, B; Ellerman, D

Bispecific antibodies in cancer immunotherapy

Dahlen, E; Veitonmaki, N; Norlen, P

Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair

Strop, P; Ho, WH; Boustany, LM

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

Yu, S; Zhang, J; Yan, Y

Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 dual-affinity ReTargeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment

LaMotte-Mohs, R; Shah, K; Smith, D

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein

Hinner, MJ; Aiba, R-SB; Wiedenmann, A

Bispecific antibodies for cancer therapy

Chames, P; Baty, D

Trastuzumab--mechanism of action and use in clinical practice

Hudis, CA

Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab)

Seimetz, D

Blinatumomab: a first-in-class Bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia

Buie, LW; Pecoraro, JJ; Horvat, TZ

4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection

Vezys, V; Penaloza-MacMaster, P; Barber, DL

CD28 co-stimulation in T-cell homeostasis: a recent perspective

Beyersdorf, N; Kerkau, T; Hunig, T

Limited cross-linking of 4-1BB by 4-1BB ligand and the agonist monoclonal antibody Utomilumab

Li, Y; Tan, S; Zhang, C

CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity

Li, J; Piskol, R; Ybarra, R

4-1BB signaling enhances primary and secondary population expansion of CD8+ T cells by maximizing Autocrine IL-2/IL-2 receptor signaling

Freitas, AA; Oh, HS; Choi, BK

4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation

Choi, BK; Lee, DY; Lee, DG

A new member of the immunoglobulin superfamily--CTLA-4

Brunet, JF; Denizot, F; Luciani, MF

Cytotoxic T-lymphocyte antigen-4 blockade in melanoma

Buchbinder, EI; McDermott, DF

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

Ishida, Y; Agata, Y; Shibahara, K

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Dong, H; Zhu, G; Tamada, K

De-novo and acquired resistance to immune checkpoint targeting

Syn, NL; Teng, MWL; Mok, TSK

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Dong, H; Strome, SE; Salomao, DR

Pembrolizumab: first global approval

Poole, RM

Atezolizumab: First Global Approval

Markham, A

Avelumab: First Global Approval

Kim, ES

Durvalumab: First Global Approval

Syed, YY

Dual checkpoint inhibition in pancreatic cancer: revealing the limitations of synergy and the potential of novel combinations

Osipov, A; Zaidi, N; Laheru, DA

Nivolumab plus ipilimumab in non-small-cell lung cancer

Reck, M; Borghaei, H; O'Byrne, KJ

Dual checkpoint inhibition with Ipilimumab plus Nivolumab after progression on sequential PD-1/PDL-1 inhibitors Pembrolizumab and Atezolizumab in a patient with lynch syndrome, metastatic colon, and localized Urothelial cancer

Winer, A; Ghatalia, P; Bubes, N

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions

Hassel, JC; Heinzerling, L; Aberle, J

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice

Du, X; Liu, M; Su, J

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

Du, X; Tang, F; Liu, M

Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy

Pol, J; Kroemer, G

Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy

Liu, Y; Zheng, P

The "don't eat me" signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma

Schurch, CM; Forster, S; Bruhl, F

Frontiers and opportunities: highlights of the 2(nd) annual conference of the Chinese antibody society

Zhang, H; Deng, M; Lin, P

Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor

Ruffo, E; Wu, RC; Bruno, TC

Role of LAG-3 in regulatory T cells

Huang, CT; Workman, CJ; Flies, D

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens

Baixeras, E; Huard, B; Miossec, C

Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo

Workman, CJ; Cauley, LS; Kim, IJ

Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3

Wang, J; Sanmamed, MF; Datar, I

Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy

Rotte, A; Jin, JY; Lemaire, V

Abstract 2719: dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses

Kraman, M; Fosh, N; Kmiecik, K

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

Engelman, JA; Zejnullahu, K; Mitsudomi, T

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, AB; Zejnullahu, K; Wu, YL

Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort

Yano, S; Yamada, T; Takeuchi, S

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

Kobayashi, S; Boggon, TJ; Dayaram, T

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Pao, W; Miller, VA; Politi, KA

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J; Brennan, C; Shih, JY

Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer

Chen, HJ; Mok, TS; Chen, ZH

A novel Bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors

Moores, SL; Chiu, ML; Bushey, BS

EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms

Lengerich, B; Agnew, C; Puchner, EM

Regulation of ERBB3/HER3 signaling in cancer

Mujoo, K; Choi, BK; Huang, Z

Abstract 637: MEHD7945A, an EGFR/ErbB3 dual specific antibody, overcomes acquired resistance to EGFR inhibitors in head and neck and lung tumors

Huang, S; Li, C; Sliwkowski, MX

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

Schaefer, G; Haber, L; Crocker, LM

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

Topalian, SL; Drake, CG; Pardoll, DM

Genomic and Transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma

Hugo, W; Zaretsky, JM; Sun, L

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Lan, Y; Zhang, D; Xu, C

Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA)

Robert, B; Dorvillius, M; Buchegger, F

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Slamon, DJ; Clark, GM; Wong, SG

A Biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy

Li, JY; Perry, SR; Muniz-Medina, V

Mechanisms underlying the action and synergism of Trastuzumab and Pertuzumab in targeting HER2-positive breast cancer

Nami, B; Maadi, H; Wang, Z

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism

Fuentes, G; Scaltriti, M; Baselga, J

Cryo-EM structure of HER2-trastuzumab-pertuzumab complex

Hao, Y; Yu, X; Bai, Y

Structural basis of a novel heterodimeric fc for bispecific antibody production

Wei, H; Cai, H; Jin, Y

Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues

Press, MF; Cordon-Cardo, C; Slamon, DJ

The predictive significance of CD20 expression in B-cell lymphomas

Prevodnik, VK; Lavrencak, J; Horvat, M

Cytokine release syndrome

Shimabukuro-Vornhagen, A; Gödel, P; Subklewe, M

CD20-TCB with Obinutuzumab pretreatment as next-generation treatment of hematologic malignancies

Bacac, M; Colombetti, S; Herter, S

FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome

Le, RQ; Li, L; Yuan, W

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

Norelli, M; Camisa, B; Barbiera, G

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia

Leong, SR; Sukumaran, S; Hristopoulos, M

Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody

Staflin, K; Zuch de Zafra, CL; Schutt, LK

Tuning T cell affinity improves efficacy and safety of anti-CD38 × anti-CD3 Bispecific antibodies in monkeys - a potential therapy for multiple myeloma

Moore, GL; Lee, S-H; Schubbert, S

Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 Bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release

Zuch de Zafra, CL; Fajardo, F; Zhong, W

Next-generation cancer immunotherapy targeting Glypican-3

Shimizu, Y; Suzuki, T; Yoshikawa, T

Glypican 3 expression in pediatric malignant solid tumors

Taguchi, T; Nakatsura, T; Oda, Y

Immunotherapeutic targeting of GPC3 in pediatric solid Embryonal tumors

Ortiz, MV; Roberts, SS; Glade Bender, J

Role of glypicans in regulation of the tumor microenvironment and cancer progression

Kaur, SP; Cummings, BS

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors

Ishiguro, T; Sano, Y; Komatsu, S-i

CD3-Bispecific antibody therapy turns solid tumors into inflammatory sites but does not install protective memory

Benonisson, H; Altintas, I; Sluijter, M

Bifunctional antibodies: concept, production and applications

Nolan, O; O'Kennedy, R

Bispecific antibodies: design, therapy, perspectives. Drug design

Sedykh, SE; Prinz, VV; Buneva, VN

Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies

Lindhofer, H; Mocikat, R; Steipe, B

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy

Seimetz, D; Lindhofer, H; Bokemeyer, C

Catumaxomab: clinical development and future directions

Linke, R; Klein, A; Seimetz, D

Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies

Spiess, C; Merchant, M; Huang, A

Engineering therapeutic bispecific antibodies using CrossMab technology

Klein, C; Schaefer, W; Regula, JT

Synergistic neutralization of pertussis toxin by a Bispecific AntibodyIn VitroandIn vivo

Wagner, EK; Wang, X; Bui, A

Engineering IgG-like Bispecific antibodies—an overview

Krah, S; Kolmar, H; Becker, S

Evolving trends in mAb production processes

Shukla, AA; Wolfe, LS; Mostafa, SS

Continuous downstream processing for high value biological products: a review

Zydney, AL

Next-generation antibody therapeutics: discovery, development and beyond: highlights of the third annual conference of the Chinese antibody society

Zhang, H; Deng, M; Pei, F

Effect of protein fusion on the transition temperature of an environmentally responsive elastin-like polypeptide: a role for surface hydrophobicity?

Trabbic-Carlson, K; Meyer, DE; Liu, L

(draft guidance): Bispecific antibody development programs

FDA Approval: Blinatumomab

Przepiorka, D; Ko, CW; Deisseroth, A

Immunogenicity of Emicizumab in people with hemophilia a (PwHA): results from the HAVEN 1-4 studies

Paz-Priel, I; Chang, T; Asikanius, E

An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection

Saber, H; Del Valle, P; Ricks, TK

Immunogenicity of mAbs in non-human primates during nonclinical safety assessment

Meer, PJK; Kooijman, M; Brinks, V

Blinatumomab: a historical perspective

Nagorsen, D; Kufer, P; Baeuerle, PA

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity

Sampei, Z; Igawa, T; Soeda, T

In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity

Ito, S; Ikuno, T; Mishima, M

How close are we to profiling immunogenicity risk using in Silico algorithms and in vitro methods?: an industry perspective

Gokemeijer, J; Jawa, V; Mitra-Kaushik, S

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity

In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity

How close are we to profiling immunogenicity risk using in Silico algorithms and in vitro methods?: an industry perspective

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Development of bispecific antibodies in China: overview and prospects

Development of bispecific antibodies in China: overview and prospects

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Development of bispecific antibodies in China: overview and prospects

Development of bispecific antibodies in China: overview and prospects

Abstract

Journal

Recommended Articles

References

Our policy towards the use of cookies